In-stent restenosis is the major problem of percutaneous coronary interventions. Drug-eluting stent became a landmark in the treatment of coronary disease. Curcumin could be used for drug-eluting stent due to its antithrombogenity and antiproliferative properties. In this paper, 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays were performed to decide the optimal concentration of curcumin for inhibiting the proliferation of vascular smooth muscle cells (VSMC). The result disclosed that more than 80% of VSMC were inhibited when the concentration of curcumin ranged from 2.5 microg/ml to 10 microg/ml (P < 0.05, compared to ethanol). Three weight percent curcumin-loaded films (3wt%, 5wt%, 8wt%) were prepared using a biodegradable polymer (poly (lactic acid-co-glycol acid), PLGA) as the carrier of curcumin. The release of lactate dehydrogenase (LDH) was used to evaluate the immediate toxicity of the curcumin-loaded PLGA films, and the three concentration curcumin-loaded films were revealed to be of no acute toxicity to the smooth muscle cells. The results of Alamar Blue test indicated that the curcumin-loaded films had better antiproliferation effect than did the 316 stainless steel (SS). Therefore, these films may be used for stent coating to inhibit the in-stent restenosis induced by VSMC proliferation.
Angioplasty, Balloon, Coronary ; Animals ; Carotid Arteries ; cytology ; Cell Proliferation ; drug effects ; Cells, Cultured ; Coated Materials, Biocompatible ; pharmacology ; Coronary Restenosis ; prevention & control ; Curcumin ; pharmacology ; Drug-Eluting Stents ; Lactic Acid ; pharmacology ; Muscle, Smooth, Vascular ; cytology ; Polyglycolic Acid ; pharmacology ; Rats

Objective:To establish a paired organoid culture system for primary pancreatic cancer lesions and liver metastatic lesions in mice, and to investigate their morphological and biological behaviors.Methods:C57BL/6 mice aged 6 to 8 weeks were selected. Pancreatic cancer PANC02 cells carrying luciferase were injected into the pancreatic tail. After monitoring the formation of liver metastases using an in vivo imaging system, mice were sacrificed, and paired primary pancreatic cancer lesions and liver metastatic lesions were extracted and cultured in an in vitro organoid culture system. The formation process of organoids was observed under an inverted phase-contrast microscope. Hematoxylin and eosin staining was used to examine the morphological structure of the organoids. The expression of epithelial cell marker CK19 and proliferation marker Ki67 in the organoids was detected by immunohistochemistry and immunofluorescence staining. The expression of invasion markers N-cadherin, E-cadherin, vimentin, snail, and MMP9 was assessed by Western blotting and immunohistochemistry. The drug sensitivity of organoids to gemcitabine was evaluated using the CellTiter-Glo ? 3D Cell Viability Assay, and the half-maximal inhibitory concentration (IC 50) of the organoids was calculated. Results:A spontaneous liver metastasis model of pancreatic cancer in mice was successfully established, along with a paired organoid culture system for primary pancreatic cancer lesions and liver metastatic lesions. The organoids grew in a spherical shape and could be passaged up to 10 generations in vitro. Both liver metastatic lesion organoids and primary pancreatic cancer lesion organoids exhibited lumen-like structures, expressed the epithelial cell marker CK19, and the proliferation marker Ki67, with a significantly higher positive ratio of Ki67 in the liver metastatic lesions compared to the primary pancreatic cancer lesions. The expression levels of invasion markers N-cadherin, vimentin, snail, and MMP9 were significantly higher in liver metastatic organoids than in primary pancreatic cancer organoids, whereas the expression level of E-cadherin was significantly lower in liver metastatic organoids. The IC 50 value of gemcitabine for liver metastatic organoids was 165.0 nM, higher than the 108.5 nM for primary pancreatic cancer organoids. Conclusions:A stable, passagable organoids of primary pancreatic cancer lesions and liver metastatic lesions in mice were successfully established.